akkermansia and glp-1 Pro Probiotic™ | Superior Supplement Products - Science First 1 Support Blend Super GLP-1 Support + Akkermansia

At La Jolla Recovery, we integrate the latest neuroscience into our treatment approach because we know that recovery is not one-size-fits-all

These effects particularly are relevant in preventing adverse remodeling and heart failure progression [43]

Coverage is plan-specific and most commercial plans still dont cover weight-loss GLP-1s as of 2026, so denials and appeals are common

Tirzepatide also carries a warning about thyroid tumors based on animal studies, though this hasnt been confirmed in humans

Due to side effects from metformin, his clinician added Ozempic, cutting his metformin dose

Biased Agonism: Does It Work?# The Evidence So Far# Two drugs in this comparison -- ecnoglutide and CT-388 -- were specifically engineered with biased agonism to improve tolerability: Ecnoglutide (cAMP-biased at GLP-1R): Discontinuation due to AEs: approximately 2%, among the lowest reported for any GLP-1 agonist Weight loss of 13.2% at 40 weeks is competitive with semaglutide-class efficacy The tolerability-to-efficacy ratio appears favorable CT-388 (signal-biased at both GLP-1R and GIPR): Despite very high Phase 1b GI rates during titration (83% nausea), Phase 2 showed only 5.9% AE discontinuation Weight loss of 22.5% at 48 weeks is among the highest in the field The tolerability-to-efficacy ratio is notable: comparable weight loss to tirzepatide with a lower discontinuation rate What the Data Suggest# The biased agonism hypothesis appears to be supported by early clinical data, though with important caveats: Biased agonists do not eliminate GI side effects -- they may reduce their severity and duration The key metric is discontinuation, not incidence -- a drug with high nausea rates but low discontinuation may indicate transient, manageable symptoms Longer and larger trials are needed -- both ecnoglutide and CT-388 have limited Phase 3 data available Patterns and Insights# More Receptors, More Side Effects# A general pattern emerges: adding receptor targets increases both efficacy and GI side effect burden